Hamilton rating scale for depression-21 modifications in patients with vagal nerve stimulation for treatment of treatment-resistant depression: Series report

Angelo Franzini, Giuseppe Messina, Carlo Marras, Mario Savino, Mario Miniati, Orso Bugiani, Giovanni Broggi

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Vagal nerve stimulation (VNS) has been approved for treatment of refractory depression (or treatment-resistant deperssion) and bipolar disorder in Europe and Canada since 2001 and in United States since 2004 by the Food and Drug Administration. Several lines of evidence support an effective antidepressant effect with such treatment modality, outcomes being mainly evaluated with Hamilton Rating Scale for Depression (HRSD). We here report a series of nine patients with severe treatment-resistant deperssion. They all underwent surgical intervention of implantation of left vagal nerve electrode at our institute. The preoperative psychiatric status and postoperative clinical outcome were both evaluated with the 21-item version of the HRSD (HRSD21). Five out of nine patients, having at least one-year follow-up, were responders (≥50% reduction of HRSD scoring) and four of these also were remitters (HRSD <10). One patient with bipolar II disorder and one patient with melancholic depression did not significantly benefit from the procedure; the latter three patients have follow-ups shorter than three months and one of them meets the remittance criteria; nonetheless, for the other two, HRSD21 score is gradually decreasing with time.

Original languageEnglish
Pages (from-to)267-271
Number of pages5
JournalNeuromodulation
Volume11
Issue number4
DOIs
Publication statusPublished - Nov 2008

Fingerprint

Treatment-Resistant Depressive Disorder
Vagus Nerve Stimulation
Depression
Bipolar Disorder
Therapeutics
United States Food and Drug Administration
Antidepressive Agents
Canada
Psychiatry
Electrodes
Economics

Keywords

  • Depression
  • Hamilton Rating Scale
  • Vagal nerve stimulation

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Neurology
  • Clinical Neurology

Cite this

Hamilton rating scale for depression-21 modifications in patients with vagal nerve stimulation for treatment of treatment-resistant depression : Series report. / Franzini, Angelo; Messina, Giuseppe; Marras, Carlo; Savino, Mario; Miniati, Mario; Bugiani, Orso; Broggi, Giovanni.

In: Neuromodulation, Vol. 11, No. 4, 11.2008, p. 267-271.

Research output: Contribution to journalArticle

@article{7f396a2521df4238a18cc24044c8716f,
title = "Hamilton rating scale for depression-21 modifications in patients with vagal nerve stimulation for treatment of treatment-resistant depression: Series report",
abstract = "Vagal nerve stimulation (VNS) has been approved for treatment of refractory depression (or treatment-resistant deperssion) and bipolar disorder in Europe and Canada since 2001 and in United States since 2004 by the Food and Drug Administration. Several lines of evidence support an effective antidepressant effect with such treatment modality, outcomes being mainly evaluated with Hamilton Rating Scale for Depression (HRSD). We here report a series of nine patients with severe treatment-resistant deperssion. They all underwent surgical intervention of implantation of left vagal nerve electrode at our institute. The preoperative psychiatric status and postoperative clinical outcome were both evaluated with the 21-item version of the HRSD (HRSD21). Five out of nine patients, having at least one-year follow-up, were responders (≥50{\%} reduction of HRSD scoring) and four of these also were remitters (HRSD <10). One patient with bipolar II disorder and one patient with melancholic depression did not significantly benefit from the procedure; the latter three patients have follow-ups shorter than three months and one of them meets the remittance criteria; nonetheless, for the other two, HRSD21 score is gradually decreasing with time.",
keywords = "Depression, Hamilton Rating Scale, Vagal nerve stimulation",
author = "Angelo Franzini and Giuseppe Messina and Carlo Marras and Mario Savino and Mario Miniati and Orso Bugiani and Giovanni Broggi",
year = "2008",
month = "11",
doi = "10.1111/j.1525-1403.2008.00174.x",
language = "English",
volume = "11",
pages = "267--271",
journal = "Neuromodulation",
issn = "1094-7159",
publisher = "Wiley-Blackwell",
number = "4",

}

TY - JOUR

T1 - Hamilton rating scale for depression-21 modifications in patients with vagal nerve stimulation for treatment of treatment-resistant depression

T2 - Series report

AU - Franzini, Angelo

AU - Messina, Giuseppe

AU - Marras, Carlo

AU - Savino, Mario

AU - Miniati, Mario

AU - Bugiani, Orso

AU - Broggi, Giovanni

PY - 2008/11

Y1 - 2008/11

N2 - Vagal nerve stimulation (VNS) has been approved for treatment of refractory depression (or treatment-resistant deperssion) and bipolar disorder in Europe and Canada since 2001 and in United States since 2004 by the Food and Drug Administration. Several lines of evidence support an effective antidepressant effect with such treatment modality, outcomes being mainly evaluated with Hamilton Rating Scale for Depression (HRSD). We here report a series of nine patients with severe treatment-resistant deperssion. They all underwent surgical intervention of implantation of left vagal nerve electrode at our institute. The preoperative psychiatric status and postoperative clinical outcome were both evaluated with the 21-item version of the HRSD (HRSD21). Five out of nine patients, having at least one-year follow-up, were responders (≥50% reduction of HRSD scoring) and four of these also were remitters (HRSD <10). One patient with bipolar II disorder and one patient with melancholic depression did not significantly benefit from the procedure; the latter three patients have follow-ups shorter than three months and one of them meets the remittance criteria; nonetheless, for the other two, HRSD21 score is gradually decreasing with time.

AB - Vagal nerve stimulation (VNS) has been approved for treatment of refractory depression (or treatment-resistant deperssion) and bipolar disorder in Europe and Canada since 2001 and in United States since 2004 by the Food and Drug Administration. Several lines of evidence support an effective antidepressant effect with such treatment modality, outcomes being mainly evaluated with Hamilton Rating Scale for Depression (HRSD). We here report a series of nine patients with severe treatment-resistant deperssion. They all underwent surgical intervention of implantation of left vagal nerve electrode at our institute. The preoperative psychiatric status and postoperative clinical outcome were both evaluated with the 21-item version of the HRSD (HRSD21). Five out of nine patients, having at least one-year follow-up, were responders (≥50% reduction of HRSD scoring) and four of these also were remitters (HRSD <10). One patient with bipolar II disorder and one patient with melancholic depression did not significantly benefit from the procedure; the latter three patients have follow-ups shorter than three months and one of them meets the remittance criteria; nonetheless, for the other two, HRSD21 score is gradually decreasing with time.

KW - Depression

KW - Hamilton Rating Scale

KW - Vagal nerve stimulation

UR - http://www.scopus.com/inward/record.url?scp=53749096502&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=53749096502&partnerID=8YFLogxK

U2 - 10.1111/j.1525-1403.2008.00174.x

DO - 10.1111/j.1525-1403.2008.00174.x

M3 - Article

C2 - 22151139

AN - SCOPUS:53749096502

VL - 11

SP - 267

EP - 271

JO - Neuromodulation

JF - Neuromodulation

SN - 1094-7159

IS - 4

ER -